Latest news about Dr Lalchandani Labs
Dr Lalchandani Labs
9.90
0.00(0.00%)
Company Performance:
View Company Insights1D0.00%
1M+0.20%
6M-30.33%
1Y+15.12%
5Y-52.43%
More news about Dr Lalchandani Labs
17Feb 26
Dr Lalchandani Labs Publishes Newspaper Notice for Rights Issue Extension
Dr Lalchandani Labs Limited has published newspaper advertisements in Financial Express and Jansatta on February 17, 2026, formally communicating the extension of its rights issue closing date from February 20 to February 27, 2026. The company also extended the on-market trading deadline for rights entitlements to February 24, 2026, with Managing Director Arjan Lal Chandani signing the regulatory submission to BSE Limited.
31Jan 26
Dr Lalchandani Labs Limited Completes Rights Issue Material Dispatch for ₹433.20 Lakhs Offering
Dr Lalchandani Labs Limited has completed dispatch of rights issue material for its ₹433.20 lakhs offering of 43,32,000 equity shares at ₹10 per share in 1:1 ratio. The issue opens February 4, 2026 and closes February 20, 2026, with mandatory ASBA process for applications and dematerialised allotment only.
20Jan 26
Dr Lalchandani Labs Approves ₹4.33 Crore Rights Issue with 1:1 Entitlement Ratio
Dr Lalchandani Labs Limited approved a rights issue of 43.32 lakh equity shares at ₹10 per share, totaling ₹4.33 crores. The 1:1 entitlement ratio allows existing shareholders to purchase one new share for every share held as of January 27, 2026 record date. The issue opens February 4, 2026 and closes February 20, 2026, potentially doubling outstanding shares to 86.65 lakh upon full subscription.
16Jan 26
Dr Lalchandani Labs Receives BSE In-Principle Approval for Rights Issue
Dr Lalchandani Labs has received BSE in-principle approval for its proposed rights issue worth ₹433.31 lakhs through reference number LOD/Rights/RB/FIP/1544/2025-26 dated January 16, 2026. The approval permits the company to proceed with issuing fully paid-up equity shares with face value of ₹10 each to eligible shareholders, subject to compliance with statutory requirements and post-issue formalities.
05Sept 25
Dr Lalchandani Labs Appoints New Independent Director and Expands Authorized Capital
Dr Lalchandani Labs Limited has announced key corporate developments following a board meeting. The company appointed Mr. Mohan Lal Gandhi as a Non-Executive Independent Director for a five-year term. The board also approved an increase in authorized capital from Rs. 4.50 crore to Rs. 11.00 crore. The company's 8th Annual General Meeting is scheduled for September 30, 2025, in New Delhi. M/s. Chauhan Pradeep & Associates has been appointed as Secretarial Auditors for a five-year term and as the scrutinizer for the upcoming AGM.
Industry Peers
Dr. Lal Path Labs
Vijaya Diagnostic Centre
Metropolis Healthcare
Thyrocare Technologies
Nephrocare Health Services
Krsnaa Diagnostics
Suraksha Diagnostic
3B BlackBio DX
Health X Platform
One Global Service Provider
1,703.70
(+3.49%)
1,300.10
(-0.21%)
508.40
(+0.20%)
470.65
(+4.08%)
649.70
(+0.92%)
566.30
(+0.26%)
299.50
(-0.02%)
1,269.60
(-1.98%)
285.50
(-2.39%)
437.90
(+2.42%)
Get More Market Insights with
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
